Merck and Co. agrees to $27.7 million payout for multiple Fosamax lawsuits

The company made the offer this week in order to lay to rest 1,200 lawsuits pending across the country

Over the past year, Merck & Co. has had a good run in fighting off plaintiffs saying the company’s osteoporosis drug Fosamax caused health problems—claiming victory in five of the seven cases to go to trial. But, the company’s victory has been knocked down by recent multidistrict litigation.

Merck has agreed to pay $27.7 million to settle hundreds of lawsuits claiming Fosamax caused osteonecrosis of the jaw. The company made the offer in a New York court this week in order to lay to rest around 1,200 lawsuits pending across the country.

Contributing Author

author image

Amanda Ciccatelli

Amanda G. Ciccatelli is a Contributing Writer for InsideCounsel, where she covers the patent litigation space. Amanda earned a B.A. in Communications and Journalism from...

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.